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Introduction
Uniparental disomy (UPD) occurs when both members
of a particular chromosome pair derive from the same
parent [1]. UPD often results from a “rescue” event; in
trisomy rescue, a disomic oocyte and a monosomic
sperm form a trisomic conceptus, and the loss of one
homolog results in a two-thirds chance of biparental
disomy and a one-third chance of maternal UPD
(mUPD). In monosomy rescue, a nullisomic oocyte and
a monosomic sperm form a monosomic conceptus, and
this duplication of the monosomic sperm results in pater-
nal UPD. Other mechanisms that can result in UPD
include post-fertilization errors (via somatic recombi-
nation or gene conversion), gametic complementation,
and somatic replacement of a derivative chromosome
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SUMMARY
Objective: To present the clinical and molecular features of a fetus with confined trisomy 16 mosaicism with
maternal uniparental disomy (UPD), using various prenatal diagnostic techniques.
Materials and Methods: Chromosomal karyotyping was performed on samples of chorionic villi, amniotic fluid
cells, amniotic membrane, umbilical cord, fetal skin, and placenta from a fetus with elevated nuchal translucency.
Polymorphic short tandem repeat markers and Affymetrix single nucleotide polymorphism (SNP) mapping chips
were used for molecular analyses.
Results: Karyotypes from chorionic villi and amniocytes showed 47,XX,+16 and 46,XX, respectively. Short tandem
repeat markers on chromosome 16 suggested maternal UPD for chromosome 16. Affymetrix 10K SNP mapping
chips were used to simultaneously confirm the difference in karyotypes between the placenta and amniocytes
and to diagnose UPD for chromosome 16. Fetal ultrasonography and magnetic resonance imaging identified
severe intrauterine growth restriction (IUGR). Autopsy revealed IUGR, incomplete lobulation of bilateral lungs,
and malrotation of the intestines. The karyotypes of umbilical cord, fetal skin and amniotic membrane were
46,XX, and the trisomy 16 karyotype appeared to be confined to the placenta.
Conclusion: UPD should be investigated as a possible etiology in all cases of unexplained IUGR. SNP microarrays
can be useful for confirming this diagnosis. [Taiwan J Obstet Gynecol 2009;48(2):152–158]
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[1,2]. During trisomy rescue, trisomies that remain in
the placental tissues may not have an immediately
lethal consequence and are referred to as confined
placental mosaicism (CPM) for trisomies [3–6].
Linkage analyses of polymorphic short tandem
repeat (STR) DNA markers from the fetus and its 
parents have been used to detect UPD [4,6,7]. Single
nucleotide polymorphism (SNP) microarrays were
recently used to identify continuous or interspersed
heterodisomic and isodisomic regions in six patients
with Silver-Russell syndrome with mUPD for chromo-
some 7 [8]. In the current study, we used Affymetrix
10K mapping chips for both microarray-based com-
parative genomic hybridization (array CGH) analysis
and detection of UPD in chromosome 16 in a fetus
presented with severe intrauterine growth restriction
(IUGR).
Case Report
A 37-year-old, gravida 5, para 1, woman had consecu-
tive, spontaneous abortions in her first two pregnan-
cies. After the successful delivery of a full-term baby
from her third pregnancy, her fourth pregnancy was
terminated owing to trisomy 21 (47,XY,+21) diagnosed
by amniocentesis. In her fifth pregnancy, an increased
thickness of nuchal translucency (NT) of 5.5 mm was
noted at 11 weeks’ gestation. The parents were coun-
seled regarding the increased risk of chromosomal
abnormalities, structural defects, and genetic syndromes.
Karyotyping of chorionic villi sampled at 12 weeks’
gestation showed 47,XX,+16 (Figure 1, upper panel).
Because of the possibility of trisomy rescue of the chro-
mosome, we performed amniocentesis at 16 weeks’ ges-
tation, which revealed a 46,XX karyotype (Figure 1,
lower panel). The discrepancy in karyotypes between
the placenta and amniocytes was confirmed using array
CGH [9] (Figure 2). Fetal ultrasonography showed se-
vere IUGR without obvious structural defects. Magnetic
resonance imaging of the fetus showed no obvious
anomalous organic structures in the brain or major
organs. Four significant markers out of the 22 STR
markers on chromosome 16 suggested the presence of
mUPD for chromosome 16 (Table 1). Affymetrix 10K
SNP mapping chips were used to confirm the diagno-
sis of UPD for chromosome 16 (UPD16) (Table 2).
The parents elected to terminate this pregnancy at 21
weeks’ gestation. Autopsy of the 151-g, female abor-
tus revealed IUGR (< fifth percentile of age-matched
controls), incomplete lobulation of bilateral lungs, and
malrotation of intestines. The karyotypes of the umbili-
cal cord, fetal skin and amniotic membrane were 46,XX,
and the trisomy of chromosome 16 appeared to be
confined to the placenta.
Materials and Methods
After informed consent was obtained from the parents,
we obtained chorionic villus tissues, amniotic fluid,
amniotic membrane, skin and placental tissue samples
from the fetus, and blood samples from both parents.
DNA was extracted from chorionic villi and amniocytes
as previously reported [10]. A panel of polymorphic
STR markers was used to analyze the origin of fetal
chromosome 16 [11] (Table 1). Affymetrix 10K map-
ping chips (Affymetrix Inc., Santa Clara, CA, USA)
were used to analyze the DNA specimens isolated from
placental tissues, amniocytes, and peripheral blood
from the parents, according to the GeneChip mapping
10K assay protocol (http://www.affymetrix.com). Ana-
lyses of array CGH were performed using the CGcgh
program as previously reported [12–14]. The CGcgh
program is freely available at http://www.mcu.edu.tw/
department/biotec/en%5Fpage/CGcgh/[9].
Using the tens of thousands of SNP markers on 
the Affymetrix 10K mapping chips, distributed among
the 23 human chromosomes, we calculated all the
possible combinations for each SNP marker among
the mother, father and fetus (Table 2). Using the fol-
lowing formula, where fo is the observed value, fe is 
the expected value and the degrees of freedom are
(m−1)× (n−1), we calculated the χ2 values and derived
p values for the normal inherited pattern or UPD for
each chromosome:
Results
Based on the χ2 values for all chromosomes using 
the tens of thousands of SNP markers in the mother,
father and fetus, the p value for chromosome 16 being
biparental was < 0.05 (p = 0.0015), whereas the p value
for UPD was > 0.99999 (Table 3). These values rejected
the hypothesis that the pair of chromosome 16s were
inherited from both the mother and father, and sup-
ported the diagnosis of UPD16. These results were in
accordance with those derived from analysis of micro-
satellite markers (Table 1). Severe IUGR of the fetus
(150 g at 21 weeks’ gestation) was compatible with the
diagnosis of UPD16. Chromosomal analyses of the fetal
umbilical cord, skin and amniotic membrane showed
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46,XX, and the trisomy 16 karyotype appeared to be
confined to the placenta (Figures 1 and 2). Based on
these results, the diagnosis was a case of a fetus with
UPD16 and CPM with trisomy 16.
Discussion
Most cases of CPM for trisomy 16 present with IUGR
and various congenital abnormalities [3–6], although
contradictory results have been reported [15]. Fetal
growth is a complex process that is regulated by fetal,
maternal and placental factors. Fetal genes are believed
to determine 50% of intrauterine growth, but maternal
nutritional status, maternal disease, and maternal be-
havior also have major impacts. The placenta is also an
important factor in regulating intrauterine growth [16].
The prevalence of CPM detected in idiopathic IUGR
pregnancies is > 20% [17,18]. UPD may exert addi-
tional adverse effects on fetal growth associated with
CPM [19]. However, a pregnancy with CPM and/or UPD
may clinically present as IUGR, but show a normal kar-
yotype after amniocentesis. CPM can often be missed,
because the placental karyotype is frequently not inves-
tigated. The chance of diagnosing UPD is even more
remote if there is no initial suspicion of CPM.
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Figure 1. Chromosomal analyses of chorionic villi (upper panel, chorionic villus sampling [CVS]) and amniocytes (lower
panel, amniocentesis). Trisomy 16 was noted only in chorionic villi (upper panel, boxed area), but not in amniocytes 
(lower panel).
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CPM with trisomy 16 has been associated with 
elevated levels of maternal serum β-human chorionic 
gonadotropin and α-fetoprotein [20]. NT screening
has been used to detect chromosomal abnormalities,
as well as congenital heart problems [21–23]. However,
no association between CPM for trisomy 16 with mUPD
and increased NT has been reported according to the
PubMed database (http://www.ncbi.nlm.nih.gov/sites/
entrez). In our case, increased NT was noted at the first-
trimester Down syndrome screening, which prompted
chorionic villus sampling. This in turn revealed placental
trisomy 16. Maternal UPD16 was finally confirmed by
fetal karyotyping and analyses of STR markers and SNP
microarrays following amniocentesis. Results of fetal
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Figure 2. Microarray-based comparative genomic hybridization using the CGcgh program. Microarray-based comparative
genomic hybridization confirmed the diagnosis of trisomy 16 in placental DNA (upper panel, boxed area) and the diagnosis of
46,XX in amniocyte DNA (lower panel).
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magnetic resonance imaging and autopsy excluded con-
genital heart diseases as the cause of increased NT in
this case, suggesting that increased NT during the first
trimester could be a primary sign of CPM for trisomy
16 with mUPD.
The American College of Medical Genetics rec-
ommends that multiple STR markers be used to iden-
tify UPD and that they should be tested for each
chromosome of interest [1]. Two fully informative loci
showing either uniparental or biparental inheritance
are the minimal requirements to make a diagnosis. 
If a chromosome of interest has at least two loci sup-
portive of the diagnosis of UPD, biparental inheritance
should be proven on all other chromosomes and mul-
tiple loci should be used to distinguish UPD from dele-
tion. In this case, we analyzed 22 STR markers and only
four were informative for maternal or paternal origins
(D16S753, D16S490, D16S3398, D16S767; Table 1).
Among those four loci, two could not exclude the pos-
sibility of maternal monosomy, thus only two out of a
panel of 22 markers (D16S3398 and D16S767; Table 1)
were fully informative. If the karyotypes of both the
Table 1. Maternal uniparental disomy was suggested using
22 short tandem repeat (STR) markers for chromosome 16
STRs Father Mother Amniocytes
D16S676 NA NA NA
D16S2640 286,290 286,290 290
D16S672 271 NA NA
D16S753* 256 254 254
D16S477 NA NA NA
D16S771 242,250 242 242
D16S310 158 158 158
D16S751 NA 226,230 226,230
D16S539 NA NA NA
D16S2622 128,140 128 128
D16S541 155 151,155 151,155
D16S750 108 108 108
D16S2618 134,137 134,137 NA
D16S687 218,226 218,222 218,222
D16S490* 338 342 342
D16S770 126 126,138 126,138
D16S526 202 202 202
D16S752 106 106,114 106,114
D16S2619 145 145,149 145,149
D16S2623 235,239 235,239 235,239
D16S3398*† 196 194,202 194,202
D16S767*† 164 160,168 160,168
*Informative for maternal or paternal origins; †fully informative.
Table 3. Statistical chances of the fetus being normal or 
having uniparental disomy (UPD)
Chromosome
p value to p value to 
be normal* be UPD*
1 0.64531 0.00044
2 0.94154 < 0.00001
3 0.43687 0.0004
4 0.73531 < 0.00001
5 0.44359 0.0003
6 0.15776 0.03565
7 0.60605 0.00015
8 0.55629 0.00006
9 0.53161 0.00319
10 0.57129 0.00043
11 0.91605 0.00104
12 0.66252 0.00337
13 0.85513 0.00018
14 0.67137 0.02781
15 0.76302 0.03301
16 0.00156 > 0.99999
17 0.86383 0.02905
18 0.88278 0.02181
19 0.78926 0.01305
20 0.85513 0.03887
21 0.87113 0.02178
22 0.75182 0.03710
*A p value < 0.05 was considered to be statistically significant.
Table 2. Possible fetal combinations of all single nucleotide polymorphism markers inherited from the mother and father
Possible 
a b c d e f g h i
combinations
Mother AA AA AA AB AB AB BB BB BB
Father AA AB BB AA AB BB AA AB BB
Fetus AA AA,AB AB,AA AA,AB AA,AB,BB AB,BB AB,AB AB,BB BB
Expected in a a b/2, b/2 c, 0 d/2, d/2 e/4, e/2, e/4 f/2, f/2 g, 0 h/2, h/2 i
normal fetus
Expected in a a b, 0 0, c 0, d 0, e, 0 f, 0 0, g 0, h i
UPD fetus
Observed a b, b1 c, c1 d, d1 e, e1, e2 f, f1 g, g1 h, h1 i
UPD = uniparental disomy.
placenta (47,XX,+16) and the fetus (46,XX) had not
been available before the STR markers were analyzed,
we would have needed an exhaustive panel of markers
for other chromosomes to confirm or exclude the
diagnosis of UPD.
Affymetrix SNP microarrays allowed us to perform
array CGH and UPD detection simultaneously. Using
the intensity of each SNP probe set on Affymetrix SNP
microarrays, we modified the freely available CGcgh
software to perform array CGH on complementary DNA
microarrays and Affymetrix 10K, 100K, 250K and 500K
microarrays [9]. Other platforms, such as Agilent
oligonucleotide microarrays (http://www.agilent.com/
chem), CMDX BAC, and oligonucleotide microarrays
(http://www.cmdiagnostics.com), which only analyze
probe intensity, can also be used to perform array CGH.
However, only the microarrays with SNP information
could be used to perform linkage analyses among the
triad of mother, father and fetus (Table 2). This genome-
wide linkage analysis using SNP information is instru-
mental in simultaneously detecting UPD for every
chromosome (Table 3).
IUGR has been associated with UPD of many chro-
mosomes, in addition to chromosome 16 [5,24–28].
Several commercial SNP microarray platforms with
increasing numbers of probes on each new microarray
are now available, and we, therefore, suggest that 
UPD should be investigated as a possible etiology in 
all cases of IUGR that cannot be explained by chro-
mosomal aneuploidy or adverse maternal medical
conditions.
Acknowledgments
The authors thank Dr Ho-Yen Chueh for sonographic
assistance and Shih-Yee Mimi Wang (University of
Illinois at Rockford, College of Medicine, USA) for
English editing.
References
1. Shaffer LG, Agan N, Goldberg JD, Ledbetter DH, Longshore
JW, Cassidy SB. American College of Medical Genetics
statement of diagnostic testing for uniparental disomy.
Genet Med 2001;3:206–11.
2. Spence JE, Perciaccante RG, Greig GM, et al. Uniparental
disomy as a mechanism for human genetic disease. Am J
Hum Genet 1988;42:217–26.
3. Wolstenholme J. Confined placental mosaicism for trisomies
2, 3, 7, 8, 9, 16, and 22: their incidence, likely origins, and
mechanisms for cell lineage compartmentalization. Prenat
Diagn 1996;16:511–24.
4. Robinson WP, Barrett IJ, Bernard L, et al. Meiotic origin of
trisomy in confined placental mosaicism is correlated with
presence of fetal uniparental disomy, high levels of trisomy
in trophoblast, and increased risk of fetal intrauterine
growth restriction. Am J Hum Genet 1997;60:917–27.
5. Lestou VS, Kalousek DK. Confined placental mosaicism and
intrauterine fetal growth. Arch Dis Child Fetal Neonatal Ed
1998;79:223–6.
6. Johnson P, Duncan K, Blunt S, Bell G, Ali Z, Cox P, Moore
GE. Apparent confined placental mosaicism of trisomy 16 and
multiple fetal anomalies: case report. Prenat Diagn 2000;20:
417–21.
7. Kalousek DK, Langlois S, Barrett I, et al. Uniparental disomy
for chromosome 16 in humans. Am J Hum Genet 1993;52:
8–16.
8. Bruce S, Leinonen R, Lindgren CM, et al. Global analysis of
uniparental disomy using high density genotyping arrays. 
J Med Genet 2005;42:847–51.
9. Lee YS, Chao A, Chao AS, et al. CGcgh: a tool for molecular
karyotyping using DNA microarray-based comparative
genomic hybridization (array-CGH). J Biomed Sci 2008;15:
687–96.
10. Lee YS, Tsai CN, Tsai CL, et al. Comparison of whole genome
amplification methods for further quantitative analysis
with microarray-based comparative genomic hybridization.
Taiwan J Obstet Gynecol 2008;47:32–41.
11. Chen CP, Chern SR, Wang TH, et al. Prenatal diagnosis and
molecular cytogenetic analysis of partial monosomy 10q
(10q25.3qter) and partial trisomy 18q (18q23qter) in
a fetus associated with cystic hygroma and ambiguous gen-
italia. Prenat Diagn 2005;25:492–6.
12. Peng HH, Wang CJ, Wang TH, Chang SD. Prenatal diagnosis
of de novo interstitial 2q14.2–2q21.3 deletion assisted by
array-based comparative genomic hybridization: a case
report. J Reprod Med 2006;51:438–42.
13. Chen CP, Lin SP, Wang TH, Chen YJ, Chen M, Wang W.
Perinatal findings and molecular cytogenetic analyses of 
de novo interstitial deletion of 9q (9q22.3q31.3) associ-
ated with Gorlin syndrome. Prenat Diagn 2006;26:725–9.
14. Chen CP, Wang TH, Chen YJ, et al. Prenatal diagnosis of
Fryns syndrome associated with a microdeletion at 8p23.1.
Prenat Diagn 2007;27:967–9.
15. Papadogiannakis N, Iwarsson E, Taimi T, Zaphiropoulos PG,
Westgren M. Lack of aneuploidy for chromosomes 15, 16,
and 18 in placentas from small-for-gestational-age liveborn
infants. Am J Obstet Gynecol 2008;198:231.e1–7.
16. Kalousek DK, Dill FJ. Chromosomal mosaicism confined 
to the placenta in human conceptions. Science 1983;221:
665–7.
17. Artan S, Bas¸aran N, Hassa H, et al. Confined placental
mosaicism in term placentae: analysis of 125 cases. Prenat
Diagn 1995;15:1135–42.
18. Wilkins-Haug L, Roberts DJ, Morton CC. Confined placental
mosaicism and intrauterine growth retardation: a case-
control analysis of placentas at delivery. Am J Obstet Gynecol
1995;172:44–50.
19. Engel E. Uniparental disomy (UPD). Genomic imprinting
and a case for new genetics (prenatal and clinical implica-
tions: the “Likon” concept). Ann Genet 1997;40:24–34.
Taiwan J Obstet Gynecol • June 2009 • Vol 48 • No 2 157
UPD in Fetus With IUGR
Taiwan J Obstet Gynecol • June 2009 • Vol 48 • No 2158
Y.K. Soong , et al
20. Groli C, Cerri V, Tarantini M, et al. Maternal serum screening
and trisomy 16 confined to the placenta. Prenat Diagn
1996;16:685–9.
21. Nicolaides KH, Heath V, Cicero S. Increased fetal nuchal
translucency at 11–14 weeks. Prenat Diagn 2002;22:308–15.
22. Hyett J. Does nuchal translucency have a role in fetal car-
diac screening? Prenat Diagn 2004;24:1130–5.
23. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen
JW Jr, Macri JN. First-trimester Down syndrome screening
using dried blood biochemistry and nuchal translucency.
Obstet Gynecol 2000;96:207–13.
24. Balmer D, Baumer A, Röthlisberger B, Schinzel A. Severe
intra-uterine growth retardation in a patient with maternal
uniparental disomy 22 and a 22-trisomic placenta. Prenat
Diagn 1999;19:1061–4.
25. Roberts E, Dunlop J, Davis GS, Churchill D, Davison EV. A fur-
ther case of confined placental mosaicism for trisomy 2
associated with adverse pregnancy outcome. Prenat Diagn
2003;23:564–5.
26. Redaelli S, Sala E, Roncaglia N, et al. Severe intrauterine
growth restriction and trisomy 15 confined placental
mosaicism: a case report and review of literature. Prenat
Diagn 2005;25:140–7.
27. Robinson WP, McGillivray B, Lewis ME, Arbour L, Barrett I,
Kalousek DK. Prenatally detected trisomy 20 mosaicism.
Prenat Diagn 2005;25:239–44.
28. Neiswanger K, Hohler PM, Hively-Thomas LB, McPherson
EW, Hogge WA, Surti U. Variable outcomes in mosaic tri-
somy 16: five case reports and literature analysis. Prenat
Diagn 2006;26:454–61.
